A medicinal chemist by training, Ejner Moltzen worked in research and development at H. Lundbeck A/S in a range of scientific, managerial and strategic positions for almost 30 years. He has been heavily involved with running efficient drug discovery projects, both in terms of delivering candidates for clinical trials and optimising the related processes.
As part of Lundbeck’s global research management team, he has been involved in driving the company’s research strategies and activities. He was also responsible for alliance management within R&D, contributing to company collaborations and public-private partnerships, and representing Lundbeck in engagement with the European Federation of Pharmaceutical Industries and Associations and the Innovative Medicines Initiative.
In 2016 he left Lundbeck to found Somami Consulting ApS, a consultancy company focused on providing support for R&D projects, operations, alliance management, strategy and policy initiatives, collaboration contracts and project evaluations. He supports both public agencies and private enterprises, nationally and internationally, and works with Innovation Fund Denmark as the agency’s lead representative on international activities relating to personalised medicine. He is currently the elected Chair of ICPermed, an EU-funded European initiative to promote implementation of personalised medicine.
